海创药业 (688302)

Hinova Pharmaceuticals Inc.

KSH

Tags

Innovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareFund Exclusive HoldingsBiological ProductsSTAR Market Growth IndexTechnology Growth LayerMargin Trading and Securities Lending

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

No latest financial report data.

2. Main Business

The main business covers:

  • Developing Best-in-class drugs with significant clinical needs.
  • Developing First-in-class (internationally pioneering) drugs.

3. Company Basic Information

  • Company Name: Hinova Pharmaceuticals Inc.
  • Listing Date: 2022-04-12
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 2 & 3, 4th Floor, Building 1, Rongyao Mansion, No. 5 Keyuan South Road, High-tech Zone, Chengdu, Sichuan Province, China
  • Website: https://www.hinovapharma.com/
  • Company Profile: Hinova Pharmaceuticals Inc. was established through the overall change of Hinova Limited. In September 2020, the board of directors and shareholders' meeting of Hinova Limited resolved to approve the overall change of Hinova Limited into a joint stock company, using August 31, 2020 as the benchmark date for the share reform. According to the "Audit Report" issued by Deloitte in September 2020, as of the audit benchmark date of August 31, 2020, the audited net asset value of Hinova Limited was RMB 1,002,668,989.56. According to the "Asset Evaluation Report" issued by Zhongfeng Evaluation in September 2020, as of the evaluation benchmark date of August 31, 2020, the evaluated net asset value of Hinova Limited was RMB 1,041,979,400. In September 2020, the board of directors and shareholders' meeting of Hinova Limited resolved to approve the conversion of the audited net asset value of Hinova Limited, RMB 1,002,668,989.56 as of August 31, 2020, into a joint stock company at a ratio of 14.53:1. After the change, the total number of shares of the joint stock company was 69,010,894 ordinary shares, with a par value of RMB 1 per share and a registered capital of RMB 69,010,894.00. The portion of net assets exceeding the registered capital, RMB 933,658,095.56, was recorded into the capital reserve of the joint stock company. All shareholders of Hinova Limited became the sponsoring shareholders of the joint stock company, holding corresponding shares in the joint stock company in proportion to their capital contributions in Hinova Limited's registered capital. In September 2020, all sponsors of Hinova Pharmaceuticals jointly signed the "Sponsor Agreement," agreeing to establish the joint stock company through overall change according to the aforementioned plan. In September 2020, Hinova Pharmaceuticals held its founding meeting and first shareholders' meeting, approved the establishment of the joint stock company through overall change according to the aforementioned plan, reviewed and passed the company's articles of association, and resolutions regarding the rules of procedure for shareholders' meetings, board of directors, and supervisory board, and elected the first directors and supervisors of Hinova Pharmaceuticals. In September 2020, Hinova Pharmaceuticals obtained the "Business License" issued by the Chengdu Market Supervision Administration. Unified social credit code: 915101000624182263.

4. Top 10 Circulating Shareholders

No circulating shareholder data.

5. Concept Sectors

No concept sector data.

Remarks

  • Data update date: Unknown
  • Data source: Public market information